Document Type : Original articles


1 Department of Medicine/Dermatology, College of Medicine, Muthanna University, Iraq.

2 Al Hussein Teaching Hospital, Muthanna Health Directorate, Samawah City, Muthanna, Iraq.


Background: Leishmaniasis is an endemic disease in Iraq. There are three types of leishmaniasis; cutaneous, mucocutaneous, and visceral form. Cutaneous leishmaniasis (CL) is the most common type that causes skin sores. In Iraq, CL has 2 presentations, zoonotic cutaneous leishmaniasis which is caused by L. major, and anthroponotic cutaneous leishmaniasis caused by L. Tropica. Leishmaniasis, is transmitted by the bite of infected female phlebotomine sandflies.
Objective: We aimed to verify the clinical and epidemiology of cutaneous leishmaniasis in the Al Muthanna governorate.
Materials and methods: A prospective cross-sectional descriptive study was carried out in the outpatient dermatological clinic in Al Hussein Teaching Hospital during the period from the 1st of December 2021 to the 1st of April 2022 in Al Muthanna governorate, Iraq. Patients with CL of any age and both sexes were enrolled in the current investigation. Detailed information regarding the age, gender, residence, duration, site, number, and type (wet or dry) of the lesion was recorded for every participant.
Results: Two hundred fifty patients were diagnosed clinically as having CL. Males represented 132 (52.8%) patients. The majority of the cases were found in the age group 0-10 (n = 174, 69.6%) patients. Eighty percent (n = 200) of the participants were from rural areas. Most of the cases were presented in less than two months (n = 164, 65.6 %). Most of the lesions affected the face (n = 89, 35.6%), and the least was seen in the upper and lower limbs (n = 9, 3.6 %). The majority of the cases had a single lesion (n = 164, 65.6%) and of the dry type (n = 178, 71.2%).
Conclusion: CL is an endemic dermatological disease in the Al Muthanna governorate. Males were outnumbering females. The highest age group affected was 0-10 years. The majority of patients were from rural areas.  The majority of the cases presented within two months, involved the face, had a single lesion, and were of a dry type.  


Main Subjects

[1]     A. A. Rahi, “Cutaneous Leishmaniasis in Iraq: A clinicoepidemiological descriptive study,” Sch. J. App. Med. Sci, vol. 1, no. 6, pp. 1021–1025, 2013.
[2]     Z. R. Al-Ani, A. M. H. Al-Hamwandi, A. A. S. Al-Ma’aeeni, and M. K. Al-Ta’aie, “Kala-azar in Al-Anbar Governorate, Western Iraq,” Anb Med J, vol. 10, no. 1, pp. 41–49, 2012.
[3]     W. H. Organization, “WHO communicable disease profile for Iraq, 2003: 39-43.” .
[4]     T. Mahnaz et al., “Leishmania major: genetic heterogeneity of Iranian isolates by single-strand conformation polymorphism and sequence analysis of ribosomal DNA internal transcribed spacer,” Acta Trop., vol. 98, no. 1, pp. 52–58, 2006.
[5]     A. Hailu, T. Gebre-Michael, N. Berhe, and M. Balkew, “Leishmaniasis,” Neglected Trop. Dis. Africa, pp. 87–112, 2016.
[6]     Q. B. Abdulla, N. P. Shabila, and T. S. Al-Hadithi, “An An outbreak of cutaneous leishmaniasis in Erbil governorate of Iraqi Kurdistan Region in 2015,” J. Infect. Dev. Ctries., vol. 12, no. 08, pp. 600–607, 2018.
[7]     M. Karami, T. Gorgani-Firouzjaee, and M. Chehrazi, “Prevalence of cutaneous Leishmaniasis in the Middle East: a systematic review and meta-analysis,” Pathog. Glob. Health, pp. 1–10, 2022.
[8]     I. Mhaidi et al., “Entomological study in an anthroponotic cutaneous leishmaniasis focus in Morocco: Fauna survey, Leishmania infection screening, molecular characterization and MALDI‐TOF MS protein profiling of relevant Phlebotomus species,” Transbound. Emerg. Dis., vol. 69, no. 3, pp. 1073–1083, 2022.
[9]     A. B. M. Al-Waaly and H. W. K. Shubber, “Epidemiological study of cutaneous leishmaniasis in Al–diwaniyah province, Iraq,” EurAsian J. Biosci., vol. 14, no. 1, pp. 269–273, 2020.
[10]   N. Salam, W. M. Al-Shaqha, and A. Azzi, “Leishmaniasis in the Middle East: incidence and epidemiology,” PLoS Negl. Trop. Dis., vol. 8, no. 10, p. e3208, 2014.
[11]   G. Nazzaro, M. Rovaris, and S. Veraldi, “Leishmaniasis: a disease with many names,” JAMA dermatology, vol. 150, no. 11, p. 1204, 2014.
[12]   R. Kumar, R. A. Bumb, N. A. Ansari, R. D. Mehta, and P. Salotra, “Cutaneous leishmaniasis caused by Leishmania tropica in Bikaner, India: parasite identification and characterization using molecular and immunologic tools,” Am. J. Trop. Med. Hyg., vol. 76, no. 5, pp. 896–901, 2007.
[13]   M. J. Al-Obaidi, M. Y. Abd Al-Hussein, and I. M. Al-Saqur, “Survey study on the prevalence of cutaneous leishmaniasis in Iraq,” Iraqi J. Sci., pp. 2181–2187, 2016.
[14]   C. Akçalı et al., “Cutaneous leishmaniasis in Hatay,” J. Turkish Acad. Dermatology, vol. 1, no. 1, 2007.
[15]   K. H. Al-Mafraji, M. G. Al-Rubaey, and K. K. Alkaisy, “Clinco-Epidemiological Study of Cutaneous Leishmaniasis in Al-Yarmouk Teaching Hospital,” IRAQI JOURNALOF COMMUNITY Med., vol. 21, no. 3, 2008.
[16]   N. A. Ahmadi, M. Modiri, and S. Mamdohi, “First survey of cutaneous leishmaniasis in Borujerd county, western Islamic Republic of Iran,” East Mediterr Heal. J, vol. 19, no. 10, pp. 847–853, 2013.
[17]   C. C. Stewart and W. R. Brieger, “Community views on cutaneous leishmaniasis in Istalif, Afghanistan: implications for treatment and prevention,” Int. Q. Community Health Educ., vol. 29, no. 2, pp. 123–142, 2009.
[18]   S. C. F. Mendonça, “Differences in immune responses against Leishmania induced by infection and by immunization with killed parasite antigen: implications for vaccine discovery,” Parasit. Vectors, vol. 9, no. 1, pp. 1–9, 2016.
[19]   Z. A. Y. Al-Khayat, N. F. S. Agha, K. I. F. Alharmni, and Y. J. Khudhur, “A clinico-epidemiological study on cutaneous leishmaniasis in Erbil, Iraq (2015-2017),” Int J Res Dermatol, vol. 4, no. 1, p. 1, 2018.
[20]   M. R. Yaghoobi Ershadi et al., “Epidemiological study in a new focus of cutaneous leishmaniasis in the Islamic Republic of Iran,” EMHJ-Eastern Mediterr. Heal. Journal, 9 (4), 816-826, 2003, 2003.
[21]   A. M. AlSamarai and H. S. AlObaidi, “Cutaneous leishmaniasis in Iraq,” J. Infect. Dev. Ctries., vol. 3, no. 02, pp. 123–129, 2009.
[22]   A. Fazaeli, B. Fouladi, and I. Sharifi, “Emergence of cutaneous leishmaniasis in a border area at south-east of Iran: an epidemiological survey,” J. Vector Borne Dis., vol. 46, no. 1, p. 36, 2009.
[23]   S. Ullah, A. H. Jan, S. M. Wazir, and N. Ali, “Prevalence of cutaneous leishmaniasis in lower Dir District (NWFP), Pakistan,” J. Pakistan Assoc. Dermatologists, vol. 19, pp. 212–215, 2009.
[24]   F. Norouzinezhad, F. Ghaffari, A. Norouzinejad, F. Kaveh, and M. M. Gouya, “Cutaneous leishmaniasis in Iran: results from an epidemiological study in urban and rural provinces,” Asian Pac. J. Trop. Biomed., vol. 6, no. 7, pp. 614–619, 2016.
[25]   L. K. J. P. 2013; 51: 75-84. Abdellatif, MZ, El-Mabrouk K, Ewis AA. An epidemiological study of cutaneous leishmaniasis in Al-jabal Al-gharbi, “An epidemiological study of cutaneous leishmaniasis in Al-jabal Al-gharbi, Libya,” Korean J. Parasitol., vol. 51, no. 1, p. 75, 2013.
[26]   A.-L. Banuls, P. Bastien, C. Pomares, J. Arevalo, R. Fisa, and M. Hide, “Clinical pleiomorphism in human leishmaniases, with special mention of asymptomatic infection,” Clin. Microbiol. Infect., vol. 17, no. 10, pp. 1451–1461, 2011.
[27]   C. da Silva Santos and C. I. Brodskyn, “The role of CD4 and CD8 T cells in human cutaneous leishmaniasis,” Front. public Heal., vol. 2, p. 165, 2014.
[28]   E. Kamali-Sarvestani, M. Rasouli, H. Mortazavi, and B. Gharesi-Fard, “Cytokine gene polymorphisms and susceptibility to cutaneous leishmaniasis in Iranian patients,” Cytokine, vol. 35, no. 3–4, pp. 159–165, 2006.
[29]   J. R. Ramírez et al., “Diagnosis of cutaneous leishmaniasis in Colombia: the sampling site within lesions influences the sensitivity of parasitologic diagnosis,” J. Clin. Microbiol., vol. 38, no. 10, pp. 3768–3773, 2000.